Category
Growth Hormone
Peptides that support the body's own growth-hormone pulses - GH secretagogues and GHRH analogs used in recovery, body-composition, and sleep-oriented protocols. This index contains 9 structured entries in the current library, including CJC-1295 (DAC), CJC-1295 (NO DAC), GHRP-2, Hexarelin, IGF-1 LR3, Ipamorelin, and other entries listed below. Their recorded statuses include Approved drug, Blend, Research peptide; those labels matter because approved-drug, investigational, reference-compound, research-peptide, and blend contexts should not be read as equivalent. Compare whether an entry is long-acting or pulse-oriented, how often it is used, and whether its timing is tied to food or sleep. Similar labels do not make the entries interchangeable, so use the detail pages to separate DAC, no-DAC, secretagogue, and approved-drug contexts. Use the comparison table as a navigation aid rather than a protocol: it summarizes status, common vial format, and recorded cycle or treatment context, while each detail page remains the authoritative location for reconstitution, format-specific U-100 draws, dosing language, timing, side effects, and practical notes. When several entries appear to fit the same broad goal, compare the simplest relevant option first, confirm that its treatment style matches the intended use, and use the linked guides for measurement and cycle-planning context.
How to compare Growth Hormone entries
Compare whether an entry is long-acting or pulse-oriented, how often it is used, and whether its timing is tied to food or sleep. Similar labels do not make the entries interchangeable, so use the detail pages to separate DAC, no-DAC, secretagogue, and approved-drug contexts.
Peptides in Growth Hormone (9)
| Peptide | Status | Common vial | Cycle length |
|---|---|---|---|
| CJC-1295 (DAC) | Research peptide | 5 mg | 6-12 weeks then reassess. |
| CJC-1295 (NO DAC) | Research peptide | 5 mg | 8-12 weeks |
| GHRP-2 | Research peptide | 5 mg | 6-10 weeks |
| Hexarelin | Research peptide | 5 mg | 4-8 weeks. |
| IGF-1 LR3 | Research peptide | 1 mg | 4-6 weeks, then 6+ weeks off |
| Ipamorelin | Research peptide | 10 mg | 8-12 weeks |
| Ipamorelin / CJC-1295 NO DAC Blend | Blend | 10 mg Ipamorelin + 10 mg CJC-1295 NO DAC | 6-12 weeks, then reassess sleep, recovery, edema, and hunger. |
| Sermorelin | Research peptide | 10 mg | 8-12 weeks |
| Tesamorelin | Approved drug | 10 mg | 12-26 weeks |
Related goal guides
Useful guides
Growth Hormone FAQ
What belongs in the Growth Hormone category?
Peptides that support the body's own growth-hormone pulses - GH secretagogues and GHRH analogs used in recovery, body-composition, and sleep-oriented protocols.
How should Growth Hormone entries be compared?
Compare whether an entry is long-acting or pulse-oriented, how often it is used, and whether its timing is tied to food or sleep. Similar labels do not make the entries interchangeable, so use the detail pages to separate DAC, no-DAC, secretagogue, and approved-drug contexts.
Where are the exact dosing and U-100 details for Growth Hormone entries?
Open an individual peptide page for its authoritative vial formats, dosing or titration schedule, timing, and notes. Use the linked calculator only after confirming the selected vial quantity and mix volume.